Condition entry page

SIBO: what the diagnosis describes, and what it does not

Small intestinal bacterial overgrowth (SIBO) is a diagnostic phenotype: a pattern of symptoms plus a supportive test result. It is not, on current evidence, a single disease with one proven root cause.

Question answered on this page

What is SIBO, and what does the diagnosis actually establish?

Short answer

SIBO describes an excess of bacteria in the small intestine, inferred in most clinical settings from a hydrogen and/or methane breath-test pattern together with compatible symptoms such as bloating, distension, altered bowel habit and post-prandial discomfort. The label identifies a phenotype, not a cause: motility disorders, altered anatomy, medication exposure, pancreatic and bile-acid factors, and prior infection are all recognised contributors, and in many people no single contributor is identified. Breath testing measures gas produced by microbial fermentation of an ingested substrate; it is an indirect proxy and its thresholds are consensus-based rather than validated against a gold standard. Recurrence after treatment is common and can reflect any of these contributors, so a recurrent pattern should not be read as evidence for one specific mechanism.

What is established

Breath testing measures exhaled hydrogen and methane produced when gut microbes ferment an ingested substrate, and interpretation thresholds come from expert consensus rather than a validated reference standard.
Population / model: Clinical consensus statement. Sources: BL-REF-0005 (verification pending).
Recognised contributors to small-intestinal overgrowth include impaired migrating motor complex activity, structural or post-surgical anatomy, acid-suppressing and opioid medication exposure, and pancreatic or bile-acid insufficiency.
Population / model: Standard gastroenterology teaching.

What human evidence shows

In human clinical practice, breath-test positivity and symptom burden correlate imperfectly, and both false positives and false negatives are described.
Population / model: Human clinical consensus / methodology. Sources: BL-REF-0005 (verification pending).
In isolated human colonocyte preparations, reducing sulfur compounds inhibit butyrate oxidation in a concentration-dependent way.
Population / model: Ex vivo human tissue. Sources: BL-REF-0011 (verification pending).

What experimental / non-human evidence shows

In mice, butyrate-driven epithelial PPAR-γ signalling limits luminal oxygen and nitrate availability and constrains expansion of facultative anaerobes.
Population / model: Mouse models. Claim BL-CLAIM-COL-002 · animal evidence · gated (blocked reference verification). Sources: BL-REF-0001 (verification pending), BL-REF-0003 (verification pending).
In the inflamed mouse gut, host-derived nitrate gives E. coli a respiratory growth advantage.
Population / model: Mouse model. Claim BL-CLAIM-NIT-001 · animal evidence · gated (blocked reference verification). Sources: BL-REF-0002 (verification pending).

What BiomeLogic (HCM) proposes — inference, not evidence

The following are BiomeLogic inferences. They are hypotheses that extend beyond the cited evidence, stated so they can be tested and discarded.

BiomeLogic proposes that in some people, epithelial metabolic state contributes to how readily an overgrowth pattern re-establishes after treatment. This extends colonic animal ecology work to a human small-intestinal question and is an inference, not evidence.
Would be falsified by: A human study in which epithelial oxidative status shows no relationship with recurrence after adjusting for motility, anatomy and medication exposure.

Alternative explanations

Motility-first
Impaired migrating motor complex clearance — post-infectious, post-surgical, neuropathic or autoimmune — is a well-recognised route to persistent overgrowth.
Anatomical / structural
Adhesions, strictures, blind loops, diverticula and altered surgical anatomy can mechanically retain content independently of any metabolic factor.
Medication and secretory factors
Acid suppression, opioids, and reduced pancreatic or bile output change the upper-GI antimicrobial environment.
Diagnostic artefact
Rapid orocaecal transit or colonic fermentation can produce a breath-test pattern read as small-intestinal, so some 'recurrence' may be measurement behaviour rather than biology.

What is not yet known

Whether breath-test phenotypes (hydrogen, methane, hydrogen sulfide) map onto distinct causal mechanisms in humans.
What proportion of recurrent cases are attributable to motility, anatomy, medication, or host epithelial factors.
Whether epithelial oxygenation, well described in mice, behaves comparably in the human small intestine.
Whether any host metabolic measurement predicts recurrence independently of established risk factors.

What evidence would discriminate these explanations

Prospective human cohorts measuring motility, anatomy, medication exposure and epithelial metabolic markers together, with recurrence as the outcome.
Direct small-intestinal sampling compared against breath-test classification in the same participants.
Intervention studies that change one candidate mechanism at a time and measure recurrence.

Sources

0 of 5 reference(s) have completed owner verification. Records awaiting verification are listed for transparency and are not presented as confirmed evidence.

BL-REF-0005verification pending
Rezaie A, Buresi M, Lembo A, et al. (2017). Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. American Journal of Gastroenterology. doi:10.1038/ajg.2017.46
https://pubmed.ncbi.nlm.nih.gov/28323273/
Scope: Clinical consensus/methodology for breath-test performance and interpretation thresholds.
Does not support: Does not establish the Host Capacity Model, and does not establish that breath testing measures small-intestinal bacterial load directly.
Status: machine cross-checked against PubMed — owner confirmation pending
BL-REF-0001verification pending
Byndloss MX, Olsan EE, Rivera-Chávez F, et al. (2017). Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science. doi:10.1126/science.aam9949
https://pubmed.ncbi.nlm.nih.gov/28798125/
Scope: Mouse/experimental epithelial ecology. Shows butyrate-driven epithelial PPAR-γ signalling limits luminal oxygen and nitrate availability and constrains Enterobacteriaceae expansion.
Does not support: Not direct proof of recurrent human SIBO, and not evidence that restoring epithelial oxidative metabolism prevents recurrence in people.
Status: machine cross-checked against PubMed — owner confirmation pending
BL-REF-0002verification pending
Winter SE, Winter MG, Xavier MN, et al. (2013). Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science. doi:10.1126/science.1232467
https://pubmed.ncbi.nlm.nih.gov/23393266/
Scope: Mouse inflamed gut. Inflammation-derived nitrate provides a respiratory growth advantage to E. coli.
Does not support: Not evidence of chronic human SIBO causation.
Status: machine cross-checked against PubMed — owner confirmation pending
BL-REF-0003verification pending
Rivera-Chávez F, Zhang LF, Faber F, et al. (2016). Depletion of butyrate-producing Clostridia from the gut microbiota drives an aerobic luminal expansion of Salmonella. Cell Host & Microbe. doi:10.1016/j.chom.2016.03.004
https://pubmed.ncbi.nlm.nih.gov/27078066/
Scope: Antibiotic/mouse model. Loss of butyrate producers raises epithelial oxygenation and permits pathogen expansion.
Does not support: Not direct proof of chronic human dysbiosis or of small-intestinal overgrowth.
Status: machine cross-checked against PubMed — owner confirmation pending
BL-REF-0011verification pending
Roediger WEW, Duncan A, Kapaniris O, Millard S (1993). Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. Gastroenterology. doi:10.1016/0016-5085(93)91016-B
https://pubmed.ncbi.nlm.nih.gov/8440437/
Scope: Isolated human colonocytes, ex vivo. Supports concentration-dependent sulfide inhibition of butyrate oxidation.
Does not support: Not in-vivo evidence, and not evidence of chronic SIBO causation.
Status: machine cross-checked against PubMed — owner confirmation pending

What this page does NOT establish

That SIBO has a single root cause, or that any one mechanism explains most cases.
That the Host Capacity Model is established, validated, or a consensus position.
That mouse colonic ecology results transfer quantitatively to the human small intestine.
Any recommendation about antimicrobials, prokinetics, diets, supplements, or dosing.

Educational systems-biology material. Not medical advice, not a diagnosis, and not a treatment recommendation. No dosing, protocol, or personal lab interpretation is given here.

What SIBO is, and what it is not

SIBO is defined by an excess of bacteria in the small intestine relative to what is normally present there. In routine practice that excess is inferred, not measured: the usual test is a breath test after a glucose or lactulose challenge, and the diagnosis is made when the gas pattern and the clinical picture line up. Culture of small-bowel aspirate is the closer measurement, but it is invasive, sampling-limited and rarely performed outside research.

That matters for how the label should be read. SIBO is a phenotype — a description of what is currently happening — rather than an explanation of why it is happening. Two people with the same breath-test result can arrive there by different routes.

What current clinical evidence supports

There is consensus guidance on how breath testing should be performed and interpreted, and there is long-standing clinical description of the conditions that predispose to overgrowth: impaired motility, altered anatomy, acid suppression, opioid exposure, and reduced pancreatic or biliary secretion. Antimicrobial therapy can reduce symptoms and normalise breath tests in a proportion of people. None of that establishes a single causal pathway.

Why recurrence can occur — several competing explanations

Recurrence is common and has more than one plausible explanation: an unaddressed motility or anatomical contributor, continued medication exposure, incomplete initial response, diagnostic misclassification, or host-side factors that are not routinely measured. This page does not adjudicate between them. The dedicated analysis lives at why overgrowth patterns can return after successful eradication.

Breath testing: what it measures and what it cannot establish

A breath test measures gases produced when microbes ferment an ingested substrate. It tells you that fermentation is occurring and roughly when. It does not directly measure bacterial load, does not localise the organisms with certainty, and its thresholds are consensus values rather than validated cut-points. Rapid transit can move substrate into the colon early and produce a rise that is read as small-intestinal.

Where experimental epithelial and ecology biology may be relevant

A body of mouse work shows that when butyrate-oxidising colonocytes are depleted, epithelial oxygen consumption falls, luminal oxygen and nitrate become more available, and facultative anaerobes expand. Human ex-vivo work shows that sulfide inhibits colonocyte butyrate oxidation in a concentration-dependent way. This is real biology in the systems where it was measured. It is colonic, largely non-human, and it has not been shown to govern recurrent small-intestinal overgrowth in people.

The Host Capacity Model extension — clearly separated

BiomeLogic's Host Capacity Model proposes that epithelial metabolic capacity is one contributor to whether a disturbed ecology re-establishes after treatment. This is a proposed integration, not a consensus position and not an established mechanism in humans. It is presented here so it can be examined and tested, and it is kept visually and structurally separate from the evidence above.

Evidence boundary matrix

Each proposition below is paired with the population it was studied in, what that evidence supports, and what it cannot support. Rows without an owner-verified source are marked as such.

Evidence boundary matrix: proposition, population or model, evidence class, what it supports, what it does not support, and sources.
Proposition	Population / model	Evidence class	What it supports	What it does NOT support	Sources
Breath testing identifies small-intestinal bacterial overgrowth.	Humans, clinical practice	Clinical consensus / methodology	A standardised, interpretable fermentation-pattern measurement.	Direct measurement of bacterial load or definitive small-intestinal localisation.	BL-REF-0005(Review or synthesis)— verification pending
Loss of butyrate-oxidising epithelium raises luminal oxygen and permits facultative anaerobe expansion.	Mice (colon)	Animal model	A mechanistic route from epithelial metabolism to microbial ecology.	That the same relationship governs human small-intestinal overgrowth or its recurrence.	BL-REF-0001(Animal model)— verification pending BL-REF-0003(Animal model)— verification pending
Host-derived nitrate favours Enterobacteriaceae growth.	Mice (inflamed gut)	Animal model	An inflammation-linked respiratory advantage for facultative anaerobes.	Chronic human SIBO causation.	BL-REF-0002(Animal model)— verification pending
Sulfide inhibits colonocyte butyrate oxidation.	Isolated human colonocytes	Ex vivo human tissue	Concentration-dependent inhibition in an isolated preparation.	In-vivo human relevance at physiological luminal concentrations.	BL-REF-0011(Ex vivo tissue)— verification pending
Epithelial metabolic capacity contributes to recurrence risk in people.	Not yet studied in humans	BiomeLogic inference (hypothesis)	A testable prediction with a stated falsification condition.	Any clinical decision, and any claim of established mechanism.	—

Research questions — what would change our mind

What human measurement would directly test whether epithelial oxygenation contributes materially to recurrent dysbiosis?
Can host epithelial metabolic state predict recurrence independently of motility and anatomical risk?
Do the hydrogen, methane and hydrogen-sulfide phenotypes correspond to distinct causal mechanisms, or to different fermentation substrates in the same underlying state?
How much apparent recurrence is diagnostic behaviour — transit-driven breath-test variability — rather than returning biology?

Page provenance

Canonical title: SIBO: what the diagnosis describes, and what it does not
Canonical URL: https://biomelogic.net/sibo
Author: Mohammed Attallah — Systems Biology Consultant
Publisher: BiomeLogic
Version: 2.0
First published: n.d.
Last substantive revision: n.d.
Last evidence review: n.d.
Evidence classes present: Clinical consensus; Ex vivo human tissue; Animal model; BiomeLogic inference (hypothesis)
Publication-eligible references: 0 of 5

Scope

A neutral orientation page for small intestinal bacterial overgrowth: what the diagnosis captures, what breath testing measures, which contributors are recognised, and where BiomeLogic's proposed extension sits relative to that evidence.

What this page does not establish

A single cause of SIBO.
That the Host Capacity Model is validated or accepted.
Any treatment, protocol, dose, or personal lab interpretation.

Cite this page

Mohammed Attallah (n.d.). SIBO: what the diagnosis describes, and what it does not (Version 2.0). BiomeLogic. https://biomelogic.net/sibo

Add BiomeLogic as a preferred source in Google

If you want to see this work more often in Google Search results, you can mark BiomeLogic as a preferred source. This is a Google setting you control; it does not change how any page here is ranked.